Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis

Table 2 Study characteristics of included clinical trials

Trial	Design	Design details	Cancer types	Enrollment size, n	ICIs	Dose, mg/kg	IrAEs, all grades, n	IrAEs, severe grades, n	mOS	mPFS
Shitara et al[17], 2018	RCT	Open-label, multicenter, phase III	Advanced GC/GEJC	294	PD-1 (pembrolizumab)	200 mg, q3w	61	10	9.1 mo (95%CI: 6.2 to 10.7 mo)	1.5 mo (95%CI: 1.4 to 2.0 mo)
Fuchs et al[18], 2022	RCT	Open-label, multicenter, phase III	Advanced GC/GEJC	294	PD-1 (pembrolizumab)	200 mg, q3w	55	11	NA	NA
Moehler et al[19], 2021	RCT	Open-label, multicenter, phase III	Advanced GC/GEJC	249	PD-L1 (avelumab)	10, q2w	32	8	10.4 mo (95%CI: 9.1 to 12.0 mo)	3.2 mo (95%CI: 2.8 to 4.1 mo)
Doi et al[20], 2019	RCT	Open-label, multicenter, phase I	Advanced GC/GEJC	40	PD-L1 (avelumab)	10, q2w	9	0	9.1 mo (95%CI: 7.2 to 11.2 mo)	2.4 mo (95%CI: 1.4 to 2.8 mo)
Doi et al[21], 2018	RCT	Open-label, multicenter, phase I	Advanced GC/GEJC	40	PD-L1 (avelumab)	10, q2w	5	0	9.1 mo (95%CI: 7.2 to 11.2 mo)	2.5 mo (95%CI: 1.4 to 2.8 mo)
Chung et al[22], 2019	RCT	Open-label, multicenter, phase I	Advanced GC/GEJC	90	PD-L1 (avelumab)	10, q2w	17	2	NA	NA
Bang et al[23], 2018	RCT	Open-label, multicenter, phase III	Advanced GC/GEJC	185	PD-L1 (avelumab)	10, q2w	12	4	4.6 mo (95%CI: 3.6 to 5.7 mo)	1.4 mo (95%CI: 1.4 to 1.5 mo)
Bang et al[24], 2017	RCT	Open-label, multicenter, phase II	Advanced GC/GEJC	57	CTLA-4 (ipilimumab)	10, q3w	10	0	12.7 mo (95%CI: 10.5 to 18.9 mo)	2.7 mo

ICIs: Immune checkpoint inhibitors; irAEs: Immune-related adverse events; mOS: Median overall survival; mPFS: Median progression-free survival; RCT: Randomized controlled trial; GC: Gastric cancer; GEJC: Gastroesophageal junction cancer; NA: Not available; PD-1: Programmed cell death receptor-1; PD-L1: Programmed death receptor-ligand 1; CTLA-4: Cytotoxic T lymphocyte-associated antigen-4.